RVL Pharmaceuticals plc (RVLPQ)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Sep 17, 2024, 4:00 PM EDT

RVL Pharmaceuticals Company Description

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary.

It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults.

The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022.

RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

RVL Pharmaceuticals plc
Country Ireland
Industry Biotechnology
Sector Healthcare
Employees 125
CEO Brian Markison

Contact Details

Address:
400 Crossing Boulevard
Bridgewater, 08807
United States
Phone 908 809 1300
Website rvlpharma.com

Stock Details

Ticker Symbol RVLPQ
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
ISIN Number IE00BF2HDL56
SIC Code 2834

Key Executives

Name Position
Brian A. Markison Chairman, President, Chief Executive Officer and Principal Financial Officer
James D. Schaub Executive Vice President and Chief Operating Officer
Christopher A. Klein General Counsel
Michael J. DePetris Principal Accounting Officer
Jarret Miller Executive Vice President of Human Resources
Scott Schroppe Secretary